Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 76Lung Neoplasms 39Carcinoma, Non-Small-Cell Lung 11Ovarian Neoplasms 5Neoplasm Metastasis 5Carcinoma, Small Cell 4Uterine Cervical Neoplasms 2Recurrence 2Pancreatic Neoplasms 2Neoplasms 2Extensive Stage Small Cell Lung Cancer 2Esophageal Neoplasms 2Carcinoma, Neuroendocrine 2Adenocarcinoma, Bronchiolo-Alveolar 2Adenocarcinoma of Lung 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1SCLC, Extensive Stage 1SCLC 1Radiation Injuries 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Unknown Primary 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1

Interventions

sotorasib 1pembrolizumab 1lorlatinib 1liposomal doxorubicin 1encorafenib 1cemiplimab 1binimetinib 1berzosertib 1Topotecan 1Taxes 1Paclitaxel 1PX-866 1NVP-BKM120 1Lomustine 1Irinotecan 1Gemcitabine 1Everolimus 1Doxorubicin 1Docetaxel 1Cetuximab 1Carboplatin 1Albumin-Bound Paclitaxel 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × Topotecan × Thoracic × Clear all
NCT04768296 2024-09-26

Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)

EMD Serono

Phase 2 Completed
76 enrolled 42 charts
Thoracic

Hereditary Sensory and Autonomic Neuropathies, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡